Browse the corpus

Opting in for MOC found with the list of contributors' names and those of ACP principal staff listed in the beginning of this book. MKSAP 19 users can opt in for simultaneous submission of CME and MOC points as they answer self assessment ques- tions. To opt in, users will be required to complete a form Language Reflecting Diversity, Equily, requesting their name, date of birth, and ABIM number. The and lnclusion Within MKSAP 19 MOC Opt-in Form will be presented during a user's first MKSAP 19's Editors and contributors commit to using CME submission and needs to be completed only once. language and images that support ACP's commitmellt to being an anti racist organization that supports diversify, ABIM Maintenance of Certification equity, and inclusion throughout health care and health Successful completion of the CME activiry which includes education. ACP also continues to ensure diversity among participation in the evaluation component, enables the par MKSAP's physician contributors. When appropriate, ticipant to earn up to 300 medical knowledge MOC points in the MKSAP Editors will also rely on MKSAP 19 Digital's the ABIM's MOC program. It is the CME activity provider's expanded use of multimedia enhancements. including video responsibility to submit participant completion information and audio, to explore and more fully explain issues sur- to ACCME for the purpose of granting MOC credit. rounding the presentation of MKSAP 19 clinical content as it relates to race and ethnicity. MKSAP 19 users are encouraged to contact the Editors at mksap-editors6lacponline.org to Disclosure Policy help us identi$z opporhrnities for improvement in this area. It is the policy of the American College of Physicians (ACP) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. To this end, and con Hospital-Based Medicine sistent with the policies of the ACP and the Accreditation For the convenience of subscribers who provide care itr Council for Continuing Medical Education (ACCME), con hospital settings, comprehensive hospital focused content tributors to all ACP continuing medical education activities aligned with the ABIM Focused Practice in tJospital Mt:dicine are required to disclose all relevant financial relationships blueprint is integrated throughout the syllabus, and self with any entity producing, marketing, re selling, or dis assessment questions that are specific to the hospital setting tributing health care goods or services consumed by, or are specially designated with the blue hospitalist icon tlEl).

Opting in for MOC found with the list of contributors' names and those of ACP principal staff listed in the beginning of this book. MKSAP 19 users can opt in for simultaneous submission of CME and MOC points as they answer self assessment ques- tions. To opt in, users will be required to complete a form Language Reflecting Diversity, Equily, requesting their name, date of birth, and ABIM number. The and lnclusion Within MKSAP 19 MOC Opt-in Form will be presented during a user's first MKSAP 19's Editors and contributors commit to using CME submission and needs to be completed only once. language and images that support ACP's commitmellt to being an anti racist organization that supports diversify, ABIM Maintenance of Certification equity, and inclusion throughout health care and health Successful completion of the CME activiry which includes education. ACP also continues to ensure diversity among participation in the evaluation component, enables the par MKSAP's physician contributors. When appropriate, ticipant to earn up to 300 medical knowledge MOC points in the MKSAP Editors will also rely on MKSAP 19 Digital's the ABIM's MOC program. It is the CME activity provider's expanded use of multimedia enhancements. including video responsibility to submit participant completion information and audio, to explore and more fully explain issues sur- to ACCME for the purpose of granting MOC credit. rounding the presentation of MKSAP 19 clinical content as it relates to race and ethnicity. MKSAP 19 users are encouraged to contact the Editors at mksap-editors6lacponline.org to Disclosure Policy help us identi$z opporhrnities for improvement in this area. It is the policy of the American College of Physicians (ACP) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. To this end, and con Hospital-Based Medicine sistent with the policies of the ACP and the Accreditation For the convenience of subscribers who provide care itr Council for Continuing Medical Education (ACCME), con hospital settings, comprehensive hospital focused content tributors to all ACP continuing medical education activities aligned with the ABIM Focused Practice in tJospital Mt:dicine are required to disclose all relevant financial relationships blueprint is integrated throughout the syllabus, and self with any entity producing, marketing, re selling, or dis assessment questions that are specific to the hospital setting tributing health care goods or services consumed by, or are specially designated with the blue hospitalist icon tlEl). used on, patients. Contributors are required to use generic names in the discussion of therapeutic options and are High Value Care Key Points required to identify any unapproved, off-label, or inves Key Points in the text that relate to High Value Care concepts tigative use of commercial products or devices. Where a (that is, concepts that discuss balancing clinical benefit with trade name is used, all available trade names for the same costs and harms) are designated by the HVC icon [HVC]. product type are also included. If trade name products manufactured by companies with whom contributors have relationships are discussed, contributors are asked to pro- Educational Disclaimer vide evidence based citations in support ofthe discussion. The editors and publisher ol MKSAP 19 recognize that the The information is reviewed by the committee responsible development of new material offers many opportunities for producing this content. If necessary adjustments to for error. Despite our best eflforts, some errors may prersist topics or contributors' roles in content development are in print. Drug dosage schedules are, we believe, accurate made to balance the discussion. A11 relevant relationships and in accordance with current standards. Readers eLre are mitigated. Readers of this content are asked to evaluate advised, however, to ensure that the recommended dos it for evidence of commercial bias and send any relevant ages in MKSAP 19 concur with the information provided comments to mksap-editors6lacponline.org so that future in the product information material. This is especialJy decisions about content and contributors can be made in important in cases of new, infrequently used, or higltly light ol this inlormation. toxic drugs. Application of the information in MKSAP 19 remains the professional responsibility of the practitioner. Mitigation of Conflicts The primary purpose of MKSAP 19 is educational. To mitigate all conflicts of interest and influences of vested Information presented, as well as publications, technologies, interests, ACP's content planners used best evidence and products, and/or services discussed, is intended to infcrrm updated clinical care guidelines in developing content, subscribers about the knowledge, techniques, and exp,sri- when such evidence and guidelines were available. All ences ofthe contributors. A diversity ofprofessional opinion content underwent review by external peer reviewers not exists, and the views of the contributors are their own and on the committee to ensure that the material was balanced not those of the ACP. Inclusion of any material in the pro- and unbiased. Contributors' disclosure information can be gram does not constitute endorsement or recommendration

used on, patients. Contributors are required to use generic names in the discussion of therapeutic options and are High Value Care Key Points required to identify any unapproved, off-label, or inves Key Points in the text that relate to High Value Care concepts tigative use of commercial products or devices. Where a (that is, concepts that discuss balancing clinical benefit with trade name is used, all available trade names for the same costs and harms) are designated by the HVC icon [HVC]. product type are also included. If trade name products manufactured by companies with whom contributors have relationships are discussed, contributors are asked to pro- Educational Disclaimer vide evidence based citations in support ofthe discussion. The editors and publisher ol MKSAP 19 recognize that the The information is reviewed by the committee responsible development of new material offers many opportunities for producing this content. If necessary adjustments to for error. Despite our best eflforts, some errors may prersist topics or contributors' roles in content development are in print. Drug dosage schedules are, we believe, accurate made to balance the discussion. A11 relevant relationships and in accordance with current standards. Readers eLre are mitigated. Readers of this content are asked to evaluate advised, however, to ensure that the recommended dos it for evidence of commercial bias and send any relevant ages in MKSAP 19 concur with the information provided comments to mksap-editors6lacponline.org so that future in the product information material. This is especialJy decisions about content and contributors can be made in important in cases of new, infrequently used, or higltly light ol this inlormation. toxic drugs. Application of the information in MKSAP 19 remains the professional responsibility of the practitioner. Mitigation of Conflicts The primary purpose of MKSAP 19 is educational. To mitigate all conflicts of interest and influences of vested Information presented, as well as publications, technologies, interests, ACP's content planners used best evidence and products, and/or services discussed, is intended to infcrrm updated clinical care guidelines in developing content, subscribers about the knowledge, techniques, and exp,sri- when such evidence and guidelines were available. All ences ofthe contributors. A diversity ofprofessional opinion content underwent review by external peer reviewers not exists, and the views of the contributors are their own and on the committee to ensure that the material was balanced not those of the ACP. Inclusion of any material in the pro- and unbiased. Contributors' disclosure information can be gram does not constitute endorsement or recommendration vl

I by the ACP. The ACP does not warrant the safety, reliability, not set up MKSAP CME/MOC accounts for purchasers of accuracy, completeness, or usefulness of and disclaims any MKSAP sold by unauthorized sellers (e.g., Amazon, eBay), and all liability for damages and claims that may result from with whom ACP has no relationship. We do not honor the use of information, publications, technologies, products, third party sales. CME credits and MOC points cannot be and/or services discussed in this program. awarded to those purchasers who have purchased the pro gram from non-authorized sellers. Permission for Use of Figures Shown in MKSAP 19 General lnternal Medicine 2 Unauthorized Use of This Book ls Multiple-Choice Ouestions Against the Law Figure shown in the critique of Self-Assessment Test Unauthorized reproduction of this publication is unlaw- Item 37 is reprinted with permission from Walker HK, ful. ACP prohibits reproduction of this publication or any Hall WD, Hurst JW, Editors. Clinical Methods: The of its parts in any form either for individual use or for \ History, Physical, and Laboratory Examinations, third distribution. :

I by the ACP. The ACP does not warrant the safety, reliability, not set up MKSAP CME/MOC accounts for purchasers of accuracy, completeness, or usefulness of and disclaims any MKSAP sold by unauthorized sellers (e.g., Amazon, eBay), and all liability for damages and claims that may result from with whom ACP has no relationship. We do not honor the use of information, publications, technologies, products, third party sales. CME credits and MOC points cannot be and/or services discussed in this program. awarded to those purchasers who have purchased the pro gram from non-authorized sellers. Permission for Use of Figures Shown in MKSAP 19 General lnternal Medicine 2 Unauthorized Use of This Book ls Multiple-Choice Ouestions Against the Law Figure shown in the critique of Self-Assessment Test Unauthorized reproduction of this publication is unlaw- Item 37 is reprinted with permission from Walker HK, ful. ACP prohibits reproduction of this publication or any Hall WD, Hurst JW, Editors. Clinical Methods: The of its parts in any form either for individual use or for \ History, Physical, and Laboratory Examinations, third distribution. : \ edition. Chapter 118, Tonometry. Boston: Butterworth ACP will consider granting an individual permission to Heinemann, 1990. Gl 1990 Butterworth Heinemann. t reproduce only limited portions of this publication for : his or her own exclusive use. Send requests in writing to \ Publisher's lnformation MKSAP- Permissions, American College of Physicians, 190 N i t Copyright Et 2022 American College of Physicians. All Independence Mall West, Philadelphia, PA 19106 7572, or ' rights reserved. email your request to mksap-editors6racponline.org. t I This publication is protected by copyright. No part of MKSAP 19 ISBN: 978-l-938245-75-6 this publication may be reproduced, stored in a retrieval General Internal Medicine 2 ISBN: 978 1 938245-83-1 t system, or transmitted in any form or by any means, elec- I t Printed in the United States of America. I tronic or mechanical, including photocopy, without the t express consent of the ACP. MKSAP 19 is for individual For order information in the U.S. or Canada, call 800-ACP- 1915. In all other countries, call 215-351-2600 (Monday i t use only. Only one account per subscription will be per- mitted for the purpose of earning CME credits and MOC to Friday, 9 eu-S prvr ET). Fax inquiries lo 215-351-2799 or t t points and for other authorized uses of MKSAP 19. email to custserv@acponline.org. L

\ edition. Chapter 118, Tonometry. Boston: Butterworth ACP will consider granting an individual permission to Heinemann, 1990. Gl 1990 Butterworth Heinemann. t reproduce only limited portions of this publication for : his or her own exclusive use. Send requests in writing to \ Publisher's lnformation MKSAP- Permissions, American College of Physicians, 190 N i t Copyright Et 2022 American College of Physicians. All Independence Mall West, Philadelphia, PA 19106 7572, or ' rights reserved. email your request to mksap-editors6racponline.org. t I This publication is protected by copyright. No part of MKSAP 19 ISBN: 978-l-938245-75-6 this publication may be reproduced, stored in a retrieval General Internal Medicine 2 ISBN: 978 1 938245-83-1 t system, or transmitted in any form or by any means, elec- I t Printed in the United States of America. I tronic or mechanical, including photocopy, without the t express consent of the ACP. MKSAP 19 is for individual For order information in the U.S. or Canada, call 800-ACP- 1915. In all other countries, call 215-351-2600 (Monday i t use only. Only one account per subscription will be per- mitted for the purpose of earning CME credits and MOC to Friday, 9 eu-S prvr ET). Fax inquiries lo 215-351-2799 or t t points and for other authorized uses of MKSAP 19. email to custserv@acponline.org. L t L Disclaimer Regarding Direct Purchases Errata and Revisions I from Online Retailers Errata and Revisions for MKSAP 19 will be available \ CME and/or MOC for MKSAP 19 is available only to custom- through MKSAP 19 Digital at mksaplg.acponline.org as t I ers who purchase the program directly from ACP. ACP will new information becomes known to the editors. , t i t t t t ] t t \ I t \ I t I t t \ ,

t L Disclaimer Regarding Direct Purchases Errata and Revisions I from Online Retailers Errata and Revisions for MKSAP 19 will be available \ CME and/or MOC for MKSAP 19 is available only to custom- through MKSAP 19 Digital at mksaplg.acponline.org as t I ers who purchase the program directly from ACP. ACP will new information becomes known to the editors. , t i t t t t ] t t \ I t \ I t I t t \ , I t t t t i tI vll t L t

: Table of Contents Routine Care of the Healthy Patient Perioperative Medicine H istory and Physical Exantinatior-r .1 General Responsibilities. . . . . 28 Periodic Health Examinatior.r. .1 Preoperative Laboratory'l'esting 28 Routine History and Physical Examination . . .1 PerioperativeMedication Management . .... 29 Screening .2 Postoperative Care. . . 29 Principles of Screening. ,2 CardiovascularPerioperative Management .. . ... 31 Screening Recommendations fbr Adults . . . . .3 Cardiovascular Risk Assessnlent. . . 31 Specific Screening l'ests . . ,4 Cardiovascular Risk Management. . 33 lmmunization 12 Pulmonary Perioperative Management 34 Vaccinations Recommended tbr All Adults . . t2 Pulmonary Risk Assessment . . . 34 Vaccinations Recommended lbr Some Adults 13 Perioperative Risk Reduction Strategies. . . . . 35 Vaccinations Recommended for Hematologic Perioperative Management 35 Specific Populations 15 Venous Thromboembolism Prophylaxis. . . . . 35 Aspirin tbr Primary Prevention 16 Perioperative Management of ,1 Healthy Lit'estyle Counseling t6 Anticoagulant Therapy Wellness 17 Perioperative Management of Antiplatelet Behavioral Counseling 17 Medications 38

Specific Screening l'ests . . ,4 Cardiovascular Risk Management. . 33 lmmunization 12 Pulmonary Perioperative Management 34 Vaccinations Recommended tbr All Adults . . t2 Pulmonary Risk Assessment . . . 34 Vaccinations Recommended lbr Some Adults 13 Perioperative Risk Reduction Strategies. . . . . 35 Vaccinations Recommended for Hematologic Perioperative Management 35 Specific Populations 15 Venous Thromboembolism Prophylaxis. . . . . 35 Aspirin tbr Primary Prevention 16 Perioperative Management of ,1 Healthy Lit'estyle Counseling t6 Anticoagulant Therapy Wellness 17 Perioperative Management of Antiplatelet Behavioral Counseling 17 Medications 38 Nutrition. 18 Perioperative Management of Anemia, Coagulopathies, and'l'hrombocytopenia . . . . 3B Physical Activity 1B Perioperative Management of Endocrine Diseases 39 Supplements and Herbal Therapies 1B Diabetes Mellitus 39 Thyroid Disease 39 Patient Safety and Ouality lmprovement Adrenal Insufficiency 39 lntroduction. .......19 40 Perioperative Management ol Kidney Disease. . . . Patient Saf'ety and Quality Issues Perioperative Management of Liver Disease. . . . . . 40 attheClinicianlevel .......19 Perioperative Management of Neurologic Disease. 47 MedicationErrors. .....19 Rheumatologic Perioperative Management. . . . . . 41 MedicationAdherence .........27 'l'ransitionsof Care Perioperative Management During .....22 Disease Modifying Antirheumatic Patient Safbty and Quality lssues at the Systems Level. . . 22 Drug and Biologic Therapy. 4t Qualitylmprovement .......... 22 Models Perioperative Management ol Special Populations 4t MeasurementofQualitylmprovement ...... 23 Geriatric Patients. 4t Patient Safety and Quality Improvement Initiatives . . . 23 Pregnant Patients 42 Patient CenteredMedical Home. .......23 HighValueCare... .....23 0besity ChcrosingWisely .......24 Defi nition and Epidemiologr 42 National Patient Saf'ety Goals . . . .24 Screening and Evaluation. . . 43 Health Infbrmation Technology and Patient Safety. . . . 24 'freatment. 43 Healthliteracy .....24 Lifestyle Modification . . 43 Pharmacologic Therapy 44 Hospital Medicine Principles Bariatric Surgery. . . . .. 44 I nterprofessional Communication and

Nutrition. 18 Perioperative Management of Anemia, Coagulopathies, and'l'hrombocytopenia . . . . 3B Physical Activity 1B Perioperative Management of Endocrine Diseases 39 Supplements and Herbal Therapies 1B Diabetes Mellitus 39 Thyroid Disease 39 Patient Safety and Ouality lmprovement Adrenal Insufficiency 39 lntroduction. .......19 40 Perioperative Management ol Kidney Disease. . . . Patient Saf'ety and Quality Issues Perioperative Management of Liver Disease. . . . . . 40 attheClinicianlevel .......19 Perioperative Management of Neurologic Disease. 47 MedicationErrors. .....19 Rheumatologic Perioperative Management. . . . . . 41 MedicationAdherence .........27 'l'ransitionsof Care Perioperative Management During .....22 Disease Modifying Antirheumatic Patient Safbty and Quality lssues at the Systems Level. . . 22 Drug and Biologic Therapy. 4t Qualitylmprovement .......... 22 Models Perioperative Management ol Special Populations 4t MeasurementofQualitylmprovement ...... 23 Geriatric Patients. 4t Patient Safety and Quality Improvement Initiatives . . . 23 Pregnant Patients 42 Patient CenteredMedical Home. .......23 HighValueCare... .....23 0besity ChcrosingWisely .......24 Defi nition and Epidemiologr 42 National Patient Saf'ety Goals . . . .24 Screening and Evaluation. . . 43 Health Infbrmation Technology and Patient Safety. . . . 24 'freatment. 43 Healthliteracy .....24 Lifestyle Modification . . 43 Pharmacologic Therapy 44 Hospital Medicine Principles Bariatric Surgery. . . . .. 44 I nterprofessional Communication and 'l'eam BasedCare. . . 25 Men's Health Consultation and Co management. . . 25 Male Sexual Dysfunction 46 Hospital Based Prevention Strategies . 27 Erectile Dysfunction 46

'l'eam BasedCare. . . 25 Men's Health Consultation and Co management. . . 25 Male Sexual Dysfunction 46 Hospital Based Prevention Strategies . 27 Erectile Dysfunction 46 lx

1 .. l Premature Ejaculation OpticNeuritis ..... 74 : Decreased Libido. Retinal Detachment 74 I Reproductive Counseling and Male Retinal Vascular Occlusion . 74 I Sterilization Retinal Artery Occlusion 74 :

Premature Ejaculation OpticNeuritis ..... 74 : Decreased Libido. Retinal Detachment 74 I Reproductive Counseling and Male Retinal Vascular Occlusion . 74 I Sterilization Retinal Artery Occlusion 74 : Androgen Deficiency Retinal Vein Occlusion . 74 I Benign Prostatic Hyperplasia. Acute Testicular and Scrotal Pain . . Ear, Nose, Mouth, and Throat Disolders Hydrocele, Varicocele, and Epididymal Cyst . Hearing Loss . . 7S Acute and Chronic Prostatitis and Pelvic Pain Tinnitus 77 Hernias. Otitis Media and Otitis Externa. 77 Cerumen Impaction 7B Women's Health Epistaxis 7B Breast Symptoms. . . Upper RespiratoryTract Infection. . . . . . 79 Breast Mass. The Common Cold . . 79 Breast Pain Sinusitis 79 Reproductive Health Rhinitis. 79 Contraception Pharyngitis. 79 Preconception Care. . . . . . . Epiglottitis BO Postpartum Care . . Salivary Gland Disorders . . . 80 Menstrual Disorders Oral Health. 81 Abnormal Uterine Bleeding Dental Disease and Infections . . . . . 81 Dysmenorrhea........... Menopause. Dermatologic Disorders Diagnosis Approach to the Patient With Dermatologic Management Disease 82 Pelvic Pain Morphologr 82 Acute PelvicPain. . ... . . . . Physical Examination 82 Chronic Pelvic Pain...... . Diagnostic Tests. . B3 Female Sexual Dysfunction . . .. Therapeutic Principles in Dermatolory . . . . B4 Vaginitis General Considerations. . . . . . B4 Bacterial Vaginosis. Topical Glucocorticoids . . . . 85 Vulvovaginal Candidiasis . . Topical Antifungal Agents 85 Trichomoniasis .......... Topical Immunomodulators B6 Topical Retinoids 86 Eye Disorders Topical Antibiotics. 86 EyeEmergencies.... Dermatitis B6 Red Eye. AtopicDermatitis... B6 Conjunctivitis ..... Contact Dermatitis 87 Keratitis HandDermatitis... 88 Episcleritis andScleritis. . . . . . Seborrheic Dermatitis. BB Uveitis. Nummular Dermatitis 89 Subconjunctival Hemorrhage . Intertrigo 89 Blepharitis Venous Stasis Dermatitis . . . 90 DryEye. Urticaria. 90 CornealAbrasions andUlcers . . . . ., DrugEruptions.... 9T Cataracts. Exanthematous (Morbilliform) . . . . . . . 9l Glaucoma. Fixed Drug Eruption. 97 Primary Open Angle Glaucoma Drug-Induced Hypersensitivity Angle Closure Glaucoma. . . . . . Syndrome (ORESS Syndrome) 9T Age-Related Macular Degeneration. . Hypersensitivity Vasculitis 93

Androgen Deficiency Retinal Vein Occlusion . 74 I Benign Prostatic Hyperplasia. Acute Testicular and Scrotal Pain . . Ear, Nose, Mouth, and Throat Disolders Hydrocele, Varicocele, and Epididymal Cyst . Hearing Loss . . 7S Acute and Chronic Prostatitis and Pelvic Pain Tinnitus 77 Hernias. Otitis Media and Otitis Externa. 77 Cerumen Impaction 7B Women's Health Epistaxis 7B Breast Symptoms. . . Upper RespiratoryTract Infection. . . . . . 79 Breast Mass. The Common Cold . . 79 Breast Pain Sinusitis 79 Reproductive Health Rhinitis. 79 Contraception Pharyngitis. 79 Preconception Care. . . . . . . Epiglottitis BO Postpartum Care . . Salivary Gland Disorders . . . 80 Menstrual Disorders Oral Health. 81 Abnormal Uterine Bleeding Dental Disease and Infections . . . . . 81 Dysmenorrhea........... Menopause. Dermatologic Disorders Diagnosis Approach to the Patient With Dermatologic Management Disease 82 Pelvic Pain Morphologr 82 Acute PelvicPain. . ... . . . . Physical Examination 82 Chronic Pelvic Pain...... . Diagnostic Tests. . B3 Female Sexual Dysfunction . . .. Therapeutic Principles in Dermatolory . . . . B4 Vaginitis General Considerations. . . . . . B4 Bacterial Vaginosis. Topical Glucocorticoids . . . . 85 Vulvovaginal Candidiasis . . Topical Antifungal Agents 85 Trichomoniasis .......... Topical Immunomodulators B6 Topical Retinoids 86 Eye Disorders Topical Antibiotics. 86 EyeEmergencies.... Dermatitis B6 Red Eye. AtopicDermatitis... B6 Conjunctivitis ..... Contact Dermatitis 87 Keratitis HandDermatitis... 88 Episcleritis andScleritis. . . . . . Seborrheic Dermatitis. BB Uveitis. Nummular Dermatitis 89 Subconjunctival Hemorrhage . Intertrigo 89 Blepharitis Venous Stasis Dermatitis . . . 90 DryEye. Urticaria. 90 CornealAbrasions andUlcers . . . . ., DrugEruptions.... 9T Cataracts. Exanthematous (Morbilliform) . . . . . . . 9l Glaucoma. Fixed Drug Eruption. 97 Primary Open Angle Glaucoma Drug-Induced Hypersensitivity Angle Closure Glaucoma. . . . . . Syndrome (ORESS Syndrome) 9T Age-Related Macular Degeneration. . Hypersensitivity Vasculitis 93 x

Stevens-Johnson Syndrome and Nail Disorders . 115 Toxic Epidermal Necrolysis Infection. . tr6 Acute Generalized Exanthematous Pustulosis, Inflammatory Nail Disorders. . . ..tt7 Pruritus IngrownToenail .... . .lt7 Acneiform Eruptions . . Melanonychia . 118 Acne Vulgaris Squamous Cell Carcinoma. . . . . . 118 Rosacea. Benign Nodules and Tumors . 119 Hidradenitis Suppurativa Seborrheic Keratosis . tLg Pigment Disorders Warts, Corns, and Skin Tags. . . . . 119 Vitiligo Dermatofibroma ... . t20 Nevi... . L20 Autoimmune Bullous Diseases DysplasticNevi ....... ....... . r2l Pemphigus Vulgaris Premalignant and Malignant Tumors . t2t Bullous Pemphigoid Actinic Keratosis . 127 Photo- or LightJnduced Dermatoses. . . . . Squamous Cell Carcinoma and Porphyria Cutanea Tarda . Keratoacanthoma. . t22 Phototoxic and Photoallergic Conditions. . . . . Basal Cell Carcinoma t23 Polymorphous Light Eruption. Melanoma L24 Superficial Skin Infections. . . . . . Inflammatory Dermatoses 126 Bacterial Skin Infections. . . . . . Psoriasis 126 Dermatophytes .... Lichen Planus 126 Yeast .. Erythema Multiforme 127 Viral Skin Infections and Exanthems . . . . . . . . Erythema Nodosum t27 Ectoparasites Erythroderma ..... t28 Lice... SweetSyndrome... t28 Scabies Bed Bugs. Bibliognphy t29 Burns . Alopecia lelf.AssesmentTest. 135 Nonscarring Localized and Generalized Alopecia Scarring Localized and Generalized Alopecia lndex 237

Stevens-Johnson Syndrome and Nail Disorders . 115 Toxic Epidermal Necrolysis Infection. . tr6 Acute Generalized Exanthematous Pustulosis, Inflammatory Nail Disorders. . . ..tt7 Pruritus IngrownToenail .... . .lt7 Acneiform Eruptions . . Melanonychia . 118 Acne Vulgaris Squamous Cell Carcinoma. . . . . . 118 Rosacea. Benign Nodules and Tumors . 119 Hidradenitis Suppurativa Seborrheic Keratosis . tLg Pigment Disorders Warts, Corns, and Skin Tags. . . . . 119 Vitiligo Dermatofibroma ... . t20 Nevi... . L20 Autoimmune Bullous Diseases DysplasticNevi ....... ....... . r2l Pemphigus Vulgaris Premalignant and Malignant Tumors . t2t Bullous Pemphigoid Actinic Keratosis . 127 Photo- or LightJnduced Dermatoses. . . . . Squamous Cell Carcinoma and Porphyria Cutanea Tarda . Keratoacanthoma. . t22 Phototoxic and Photoallergic Conditions. . . . . Basal Cell Carcinoma t23 Polymorphous Light Eruption. Melanoma L24 Superficial Skin Infections. . . . . . Inflammatory Dermatoses 126 Bacterial Skin Infections. . . . . . Psoriasis 126 Dermatophytes .... Lichen Planus 126 Yeast .. Erythema Multiforme 127 Viral Skin Infections and Exanthems . . . . . . . . Erythema Nodosum t27 Ectoparasites Erythroderma ..... t28 Lice... SweetSyndrome... t28 Scabies Bed Bugs. Bibliognphy t29 Burns . Alopecia lelf.AssesmentTest. 135 Nonscarring Localized and Generalized Alopecia Scarring Localized and Generalized Alopecia lndex 237 xt